Cargando…

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

The capsid assembly modulator JNJ‐56136379 (bersacapavir) disrupts hepatitis B virus replication. It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug‐drug interactions of JNJ‐56136379 when combined with drugs that inhibit or are metabolized by CYP3A. In a phase 1, open...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandenbossche, Joris, Yogaratnam, Jeysen, Hillewaert, Vera, Rasschaert, Freya, Talloen, Willem, Biewenga, Jeike, Snoeys, Jan, Kakuda, Thomas N., Palmer, Martyn, Nangosyah, Julius, Biermer, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087559/ https://www.ncbi.nlm.nih.gov/pubmed/36062869 http://dx.doi.org/10.1002/cpdd.1164

Ejemplares similares

Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection
por: Janssen, Harry L A, et al.
Publicado: (2023)

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
por: Gane, Ed J., et al.
Publicado: (2022)

Absence of QTc Prolongation with Domperidone: A Randomized, Double-Blind, Placebo- and Positive-Controlled Thorough QT/QTc Study in Healthy Volunteers
por: Biewenga, Jeike, et al.
Publicado: (2015)

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic Study
por: Kurosawa, Ken, et al.
Publicado: (2021)

The viral capsid as novel nanomaterials for drug delivery
por: Aljabali, Alaa AA, et al.
Publicado: (2021)

JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study
por: Takehara, Tetsuo, et al.
Publicado: (2020)

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
por: Bourgeois, Stefan, et al.
Publicado: (2017)

Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2021)

Folding of the rabbit hemorrhagic disease virus capsid protein and delineation of N-terminal domains dispensable for assembly
por: Laurent, S., et al.
Publicado: (2014)

JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies
por: Brahmer, Julie R., et al.
Publicado: (2020)

All-Atom Molecular Dynamics of Virus Capsids as Drug Targets
por: Perilla, Juan R., et al.
Publicado: (2016)

JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015)

Author Correction: Preclinical and clinical characterization of the RORγt inhibitor JNJ-61803534
por: Xue, Xiaohua, et al.
Publicado: (2022)

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
por: Neijssen, Joost, et al.
Publicado: (2021)

A study on the effect of JNJ-10397049 on proliferation and differentiation of neural precursor cells
por: Karami, Neda, et al.
Publicado: (2022)

Drugs that act on the respiratory tract
por: Yogaratnam, Dinesh, et al.
Publicado: (2021)

Vibratile Cells in the Bronchial Mucous Membrane
por: Biermer, M.
Publicado: (1853)

Complementary pharmacokinetic measures to further define the profile of once-daily OROS hydromorphone ER during single-dose and steady-state dosing
por: Devarakonda, Krishna, et al.
Publicado: (2013)

Searching for drug leads targeted to the hydrophobic cleft of dengue virus capsid protein
por: Ortlieb, Liliane O., et al.
Publicado: (2021)

Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813
por: Lavreysen, Hilde, et al.
Publicado: (2015)

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005
por: Martinon-Torres, Federico, et al.
Publicado: (2018)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Opposite Effects of Mepyramine on JNJ 7777120-Induced Amelioration of Experimentally Induced Asthma in Mice in Sensitization and Provocation
por: Beermann, Silke, et al.
Publicado: (2012)

A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia
por: Covington, Paul S., et al.
Publicado: (2013)

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer
por: Verstraete, Maud, et al.
Publicado: (2015)

Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor
por: Lavreysen, Hilde, et al.
Publicado: (2015)

CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
por: Mancuso, Renzo, et al.
Publicado: (2019)

Dataset of eyeblink conditioning in mice treated with the selective mGluR1 antagonist JNJ16259685
por: Tohyama, Shoichi, et al.
Publicado: (2023)

JNJ-64619178 radiosensitizes and suppresses fractionated ionizing radiation-induced neuroendocrine differentiation (NED) in prostate cancer
por: Pawar, Jogendra Singh, et al.
Publicado: (2023)

PEGylated thrombopoietin mimetic, JNJ‑26366821 a novel prophylactic radiation countermeasure for acute radiation injury
por: Holmes-Hampton, Gregory P., et al.
Publicado: (2023)

Exosite 1 thrombin inhibition with JNJ-64179375 inhibits thrombus formation in a human translational model of thrombosis
por: Wilson, Simon J, et al.
Publicado: (2019)

Mitigation of total body irradiation-induced mortality and hematopoietic injury of mice by a thrombopoietin mimetic (JNJ-26366821)
por: Kumar, Vidya P., et al.
Publicado: (2022)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel, Danielle, et al.
Publicado: (2021)

Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-γ Agonist
por: Clarke, Holly J., et al.
Publicado: (2008)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Sustained release of the candidate antiretroviral peptides T-1249 and JNJ54310516-AFP from a rod insert vaginal ring
por: Murphy, Diarmaid J., et al.
Publicado: (2016)

Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
por: Salvadore, Giacomo, et al.
Publicado: (2020)

A Selective Histamine H4 Receptor Antagonist, JNJ7777120, Role on glutamate Transporter Activity in Chronic Depression
por: Yeni, Yesim, et al.
Publicado: (2022)

Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
por: Brehmer, Dirk, et al.
Publicado: (2021)

Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
por: Wang, Judy, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nsee7ud02121mt8opdi79bo8k7